EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its plans to initiate the first of five phase 2 clinical studies of AL001. The ...
latestnewsandupdates49 分钟
The Turin Thyssenkrupp accident and the long legal battles
The fire toThyssenkrupp steelworks of Turinwhich took place in the night between the 5 And December 6, 2007was a serious ...